Oppenheimer increased its Alimera Sciences ALIM price target from $4 to $7 in a research report published today.
In the report, Oppenheimer stated, "We believe ALIM is leaning toward a commercialization partnership, which would bring in needed capital near-term. We believe ALIM is substantially undervalued on Iluvien's E.U. opportunity."
Shares of Alimera Sciences closed today at $3.94, up 70.56% from Monday's market close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in